Portfolio company
CanSense
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops blood-based diagnostic tests using laser spectroscopy and artificial intelligence for early-stage bowel cancer detection for healthcare providers and laboratories.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Digistain
This company develops a diagnostic test using infrared spectroscopy to provide breast cancer recurrence-risk stratification for oncologists and multidisciplinary clinical teams.
Voc Diagnostics
This company develops diagnostic instruments using machine learning and sensor technology to detect ovarian cancer from blood plasma samples for healthcare providers.
OXCan
This company develops blood tests using proteomics and machine learning to enable early cancer detection for healthcare providers and patients.
20/20 BioLabs
This company develops AI-powered blood tests for the early detection and prevention of cancers and chronic diseases for individuals and healthcare providers.
Cancilico
Cancilico develops AI-powered software for automated bone marrow cell classification and counting to assist diagnostic laboratories in identifying blood cancers.
Waiv
This company develops artificial intelligence diagnostic tests and digital pathology software for oncology laboratories and healthcare providers to improve cancer patient treatment decisions.
Glycanostics
This digital health company develops non-invasive liquid biopsy tests for early-stage cancer detection, serving clinical laboratories, hospitals and oncology professionals.
Oncascan
Oncascan developed a non-invasive blood test to detect cancer sensitivity in lymphocytes for clinical laboratories to improve patient management and diagnostic accuracy.
